132 related articles for article (PubMed ID: 21975337)
1. A safety and toxicity assessment of the administration of multiple intracerebral injections of irinotecan or doxorubicin drug-eluting beads.
Held N; Lewis AL; Hedrich HJ; Brinker T; Glage S
Clin Transl Oncol; 2011 Oct; 13(10):742-6. PubMed ID: 21975337
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of biocompatibility and anti-glioma efficacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate.
Glage S; Lewis AL; Mertens P; Baltes S; Geigle P; Brinker T
Clin Transl Oncol; 2012 Jan; 14(1):50-9. PubMed ID: 22262719
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.
Baltes S; Freund I; Lewis AL; Nolte I; Brinker T
J Mater Sci Mater Med; 2010 Apr; 21(4):1393-402. PubMed ID: 20162337
[TBL] [Abstract][Full Text] [Related]
4. Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin.
Eyol E; Boleij A; Taylor RR; Lewis AL; Berger MR
Clin Exp Metastasis; 2008; 25(3):273-82. PubMed ID: 18259882
[TBL] [Abstract][Full Text] [Related]
5. Treatment of experimental pancreatic cancer by doxorubicin-, mitoxantrone-, and irinotecan-drug eluting beads.
Yagublu V; Caliskan N; Lewis AL; Jesenofsky R; Gasimova L; Löhr JM; Keese M
Pancreatology; 2013; 13(1):79-87. PubMed ID: 23395574
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
7. Improvement of survival in C6 rat glioma model by a sustained drug release from localized PLGA microspheres in a thermoreversible hydrogel.
Ozeki T; Kaneko D; Hashizawa K; Imai Y; Tagami T; Okada H
Int J Pharm; 2012 May; 427(2):299-304. PubMed ID: 22366485
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan.
Jordan O; Denys A; De Baere T; Boulens N; Doelker E
J Vasc Interv Radiol; 2010 Jul; 21(7):1084-90. PubMed ID: 20610183
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy compared between irinotecan-loaded microspheres HepaSphere and DC bead in a model of VX2 liver metastases in the rabbit.
Namur J; Pascale F; Maeda N; Sterba M; Ghegediban SH; Verret V; Paci A; Seck A; Osuga K; Wassef M; Reb P; Laurent A
J Vasc Interv Radiol; 2015 Jul; 26(7):1067-1075.e3. PubMed ID: 25952641
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
Clarke JL; Molinaro AM; Cabrera JR; DeSilva AA; Rabbitt JE; Prey J; Drummond DC; Kim J; Noble C; Fitzgerald JB; Chang SM; Butowski NA; Taylor JW; Park JW; Prados MD
Cancer Chemother Pharmacol; 2017 Mar; 79(3):603-610. PubMed ID: 28233053
[TBL] [Abstract][Full Text] [Related]
11. Altered irinotecan metabolism in a patient receiving phenytoin.
Mathijssen RH; Sparreboom A; Dumez H; van Oosterom AT; de Bruijn EA
Anticancer Drugs; 2002 Feb; 13(2):139-40. PubMed ID: 11901305
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model.
Gholamrezanezhad A; Mirpour S; Geschwind JF; Rao P; Loffroy R; Pellerin O; Liapi EA
Eur Radiol; 2016 Oct; 26(10):3474-82. PubMed ID: 26780638
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of EUS-guided injection of irinotecan-loaded microspheres into the swine pancreas.
Karaca C; Cizginer S; Konuk Y; Kambadakone A; Turner BG; Mino-Kenudson M; Sahani DV; Macfarlane C; Brugge W
Gastrointest Endosc; 2011 Mar; 73(3):603-6. PubMed ID: 21238959
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
Nomura H; Tsuda H; Kataoka F; Chiyoda T; Yamagami W; Tominaga E; Susumu N; Aoki D
Eur J Gynaecol Oncol; 2012; 33(1):86-9. PubMed ID: 22439412
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
Buckner JC; Reid JM; Wright K; Kaufmann SH; Erlichman C; Ames M; Cha S; O'Fallon JR; Schaaf LJ; Miller LL
Cancer; 2003 May; 97(9 Suppl):2352-8. PubMed ID: 12712456
[TBL] [Abstract][Full Text] [Related]
16. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study.
Venturini M; Sallemi C; Agostini G; Marra P; Cereda S; Reni M; Aldrighetti L; De Cobelli F; Del Maschio A
Br J Radiol; 2016 Nov; 89(1067):20160247. PubMed ID: 27558984
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
[TBL] [Abstract][Full Text] [Related]
18. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases.
Tang Y; Czuczman PR; Chung ST; Lewis AL
J Control Release; 2008 Apr; 127(1):70-8. PubMed ID: 18237814
[TBL] [Abstract][Full Text] [Related]
19. Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization.
Kaiser J; Thiesen J; Krämer I
J Oncol Pharm Pract; 2010 Mar; 16(1):53-61. PubMed ID: 19617306
[TBL] [Abstract][Full Text] [Related]
20. Local implantation of doxorubicin drug eluting beads in rat glioma.
Vinchon-Petit S; Jarnet D; Michalak S; Lewis A; Benoit JP; Menei P
Int J Pharm; 2010 Dec; 402(1-2):184-9. PubMed ID: 20863875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
